Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAVE study of efgartigimod PH20 SC versus rituximab in ANCA-associated vasculitis
jRCT2071260102Phase 2Not yet recruiting
- Sponsor
- Atushi Kawakami
- Start
- Nov 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) comparing efgartigimod PH20 SC plus reduced-dose glucocorticoids with rituximab plus reduced-dose glucocorticoids (2 arms). Primary endpoint: Remission at Week 26 without glucocorticoids. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfcrituximabprednisolonemethylprednisolone
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)microscopic polyangiitis (MPA)granulomatosis with polyangiitis (GPA)
Beyond the preview
Go deeper on jRCT2071260102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260102.